Novartis Bioventures Ltd - Net Worth and Insider Trading

Novartis Bioventures Ltd Net Worth

The estimated net worth of Novartis Bioventures Ltd is at least $169 Million dollars as of 2024-06-09. Novartis Bioventures Ltd is the 10% Owner of Ra Pharmaceuticals Inc and owns about 2,251,457 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $108 Million. Novartis Bioventures Ltd is the 10% Owner of Bicycle Therapeutics PLC and owns about 1,769,641 shares of Bicycle Therapeutics PLC (BCYC) stock worth over $41 Million. Novartis Bioventures Ltd is also the of Akouos Inc and owns about 1,181,258 shares of Akouos Inc (AKUS) stock worth over $16 Million. Besides these, Novartis Bioventures Ltd also holds Spyre Therapeutics Inc (SYRE) , Aerpio Pharmaceuticals Inc (ARPO) , Aileron Therapeutics Inc (ALRN) , Galera Therapeutics Inc (GRTX) , Proteostasis Therapeutics Inc (PTI) . Details can be seen in Novartis Bioventures Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Novartis Bioventures Ltd has not made any transactions after 2020-06-30 and currently still holds the listed stock(s).

Transaction Summary of Novartis Bioventures Ltd

To

Novartis Bioventures Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Novartis Bioventures Ltd owns 17 companies in total, including Akouos Inc (AKUS) , Forma Therapeutics Holdings Inc (FMTX) , and Galera Therapeutics Inc (GRTX) among others .

Click here to see the complete history of Novartis Bioventures Ltd’s form 4 insider trades.

Insider Ownership Summary of Novartis Bioventures Ltd

Ticker Comapny Transaction Date Type of Owner
AKUS Akouos Inc 2020-06-30 10 percent owner
FMTX Forma Therapeutics Holdings Inc 2020-06-18 10 percent owner
GRTX Galera Therapeutics Inc 2020-06-19 10 percent owner
LIMIT LIMIT 2019-05-28 10 percent owner
LIMIT LIMIT 2019-04-26 10 percent owner
LIMIT LIMIT 2019-04-01 10 percent owner
LIMIT LIMIT 2017-05-04 10 percent owner
LIMIT LIMIT 2018-05-11 10 percent owner
LIMIT LIMIT 2017-06-19 10 percent owner
LIMIT LIMIT 2016-02-17 10 percent owner
LIMIT LIMIT 2014-09-16 10 percent owner
LIMIT LIMIT 2014-03-19 10 percent owner
LIMIT LIMIT 2014-01-29 10 percent owner
LIMIT LIMIT 2010-07-21 10 percent owner
LIMIT LIMIT 2017-03-15 10 percent owner
LIMIT LIMIT 2016-02-10 10 percent owner
LIMIT LIMIT 2016-02-10 10 percent owner

Novartis Bioventures Ltd Latest Holdings Summary

Novartis Bioventures Ltd currently owns a total of 8 stocks. Among these stocks, Novartis Bioventures Ltd owns 2,251,457 shares of Ra Pharmaceuticals Inc (RARX) as of June 19, 2017, with a value of $108 Million and a weighting of 64.03%. Novartis Bioventures Ltd owns 1,769,641 shares of Bicycle Therapeutics PLC (BCYC) as of May 28, 2019, with a value of $41 Million and a weighting of 24.16%. Novartis Bioventures Ltd also owns 1,181,258 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $16 Million and a weighting of 9.3%. The other 5 stocks Spyre Therapeutics Inc (SYRE) , Aerpio Pharmaceuticals Inc (ARPO) , Aileron Therapeutics Inc (ALRN) , Galera Therapeutics Inc (GRTX) , Proteostasis Therapeutics Inc (PTI) have a combined weighting of 2.51% among all his current holdings.

Latest Holdings of Novartis Bioventures Ltd

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
RARX Ra Pharmaceuticals Inc 2017-06-19 2,251,457 47.99 108,047,421
BCYC Bicycle Therapeutics PLC 2019-05-28 1,769,641 23.04 40,772,529
AKUS Akouos Inc 2020-06-30 1,181,258 13.29 15,698,919
SYRE Spyre Therapeutics Inc 2018-05-11 87,013 33.67 2,929,728
ARPO Aerpio Pharmaceuticals Inc 2019-04-26 269,988 2.20 593,974
ALRN Aileron Therapeutics Inc 2019-04-01 103,970 3.24 336,863
GRTX Galera Therapeutics Inc 2020-06-19 2,467,961 0.11 269,008
PTI Proteostasis Therapeutics Inc 2016-02-17 93,690 1.11 103,996

Holding Weightings of Novartis Bioventures Ltd


Novartis Bioventures Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 56,420 shares on June 19, 2017, which brought Novartis Bioventures Ltd around $1 Million.

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 0 transactions in Bicycle Therapeutics PLC (BCYC) over the past 5 years. The most-recent trade in Bicycle Therapeutics PLC is the acquisition of 168,630 shares on May 28, 2019, which cost Novartis Bioventures Ltd around $2 Million.

According to the SEC Form 4 filings, Novartis Bioventures Ltd has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 125,000 shares on June 30, 2020, which cost Novartis Bioventures Ltd around $2 Million.

More details on Novartis Bioventures Ltd's insider transactions can be found in the Insider Trading History of Novartis Bioventures Ltd table.

Insider Trading History of Novartis Bioventures Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Novartis Bioventures Ltd Trading Performance

GuruFocus tracks the stock performance after each of Novartis Bioventures Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Novartis Bioventures Ltd is 9.13%. GuruFocus also compares Novartis Bioventures Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Novartis Bioventures Ltd within 3 months outperforms 3 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Novartis Bioventures Ltd's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Novartis Bioventures Ltd

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
3 out of 7 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.78 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.07 LIMIT LIMIT LIMIT LIMIT LIMIT

Novartis Bioventures Ltd Ownership Network

Ownership Network List of Novartis Bioventures Ltd

No Data

Ownership Network Relation of Novartis Bioventures Ltd

Insider Network Chart

Novartis Bioventures Ltd Owned Company Details

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Novartis Bioventures Ltd is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Akouos Inc Insider Transactions

No Available Data

Novartis Bioventures Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Novartis Bioventures Ltd. You might contact Novartis Bioventures Ltd via mailing address: C/o Novartis International Ag, Wsj-200.220, Ch-4002 Basel V8 0000000000.

Discussions on Novartis Bioventures Ltd

No discussions yet.